Cardio Diagnostics Holdings, Inc. Operating Lease Right-of-Use Assets
Cardio Diagnostics Holdings, Inc. (CDIO) had Operating Lease Right-of-Use Assets of $169.12 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-07
- 2026-06-30: Operating Lease, Right-of-Use Asset $169.12K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $214.69K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $259.56K.
- 2025-09-30: Operating Lease, Right-of-Use Asset $303.77K.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $169.12K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $214.69K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $259.56K 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $303.77K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $347.30K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $390.17K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $432.40K 10-K · filed 2026-03-13 | $575.23K 10-Q · filed 2024-05-15 |
| 2024-09-30 | $473.98K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $514.94K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $555.27K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $575.23K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $879.28K 10-Q · filed 2023-11-13 | |
| 2023-08-01 | $663.88K 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |